Diabetic Retinopathy Treatment Market Size, Share Analysis and Forecast Report (2026-2035)

Diabetic Retinopathy Treatment Market Overview

Diabetic retinopathy (DR) is the damage caused to the blood vessels in the retina by diabetes mellitus. There are two types of this condition, namely, non-proliferative and proliferative or progressed DR. It is caused by changes in blood glucose levels, which cause abnormal growth of the light-sensitive tissues in the eye. The common symptoms include dark spots or floating strings in the vision field, blurred or fluctuating vision, impaired colour vision, or vision loss. 

Diabetic Retinopathy Treatment Market Growth Drivers

Growing Cases of Diabetes Augmenting the Market Growth

Diabetes causes damage to the eyes, thus, the growing cases of diabetes among the world population are expected to accelerate market growth. The favourable government policies to make advanced healthcare services available to the masses and extensive research and development activities are likely to generate various new opportunities that will impact diabetic retinopathy treatment market value in the forecast period. Additionally, the expansion of healthcare infrastructure and the rising demand for early detection technologies are some of the other driving factors for the DR treatment market. The clinical pipeline for DR seems full of promises, with lots of drugs under the umbrella specifically targeting diabetic retinopathy among diabetic patients. Moreover, technological advancements in ophthalmic surgical and diagnostic instruments will aid the growth of the diabetic retinopathy treatment market during the forecast years. 

Regulatory Approvals to Meet Rising Diabetic Retinopathy Treatment Market Demand

The market is witnessing significant regulatory approvals by the authorities including the FDA. For instance, in April 2024, AEYE Health, the leading company for AI retinal imaging and diagnostics, received the first-ever FDA clearance for a fully autonomous artificial intelligence (AI) capable of diagnosing referable diabetic retinopathy from retinal images obtained by a handheld camera.  
This new FDA clearance is based on two large-scale prospective phase-III studies, in which AEYE-DS demonstrated best-in-class efficacy and imageability. 

According to the estimates by the CCD’s Vision and Eye Health Surveillance System, there were an estimated 9.6 million people in the United States suffering from diabetic retinopathy (DR) in 2021.  This new device is a combination of a fully autonomous AI with a portable handheld device, bringing a new and affordable screening solution to address enabling increasing early detection rates and driving retinopathy management in the market. These advancements contribute to the market's growth by addressing a critical need for efficient, accessible screening solutions.

Diabetic Retinopathy Treatment Market Trends

Diabetic Retinopathy Treatment Market Segmentation

Diabetic Retinopathy Treatment Market Share

Market Share by Indication to Witness Substantial Growth

Based on Indication, the market is divided into proliferative diabetic retinopathy and non-proliferative diabetic retinopathy. The non-proliferative diabetic retinopathy NPDR segment leads the market share due to the higher prevalence which is the prior stage of diabetic retinopathy. It is commonly asymptomatic but can progress to vision-threatening conditions if untreated, making early diagnosis and treatment crucial. This contributes to the high demand for therapies such as anti-VEGF injections and laser treatments compared to proliferative diabetic retinopathy (PDR).

Purchase the Regional Overview for USD 1099

If you choose to purchase the full report at a later stage, the amount already paid will be adjusted, and you will only need to pay the remaining balance.

Purchase the Regional Overview for USD 1099

If you choose to purchase the full report at a later stage, the amount already paid will be adjusted, and you will only need to pay the remaining balance.

Purchase the Regional Overview for USD 1099

If you choose to purchase the full report at a later stage, the amount already paid will be adjusted, and you will only need to pay the remaining balance.

Diabetic Retinopathy Treatment Market Analysis by Region

The United States is expected to lead the market due to the high market penetration of anti-VEGF drugs such as Eylea, Avastin, and Lucentis. The market is also expected to grow in the region owing to the supportive reimbursement policies and the increasing prevalence of diabetes. The increasing awareness regarding the availability of advanced options for treating diabetic retinopathy also adds to the regional market growth. The market is driven by the availability of modern healthcare infrastructure, favourable government initiatives about medication research, and high patient and practitioner awareness levels. 

On the other hand, the Japanese market is expected to expand at a significant growth rate because of the surging geriatric population, high healthcare expenditure, large patient pool, innovation in diagnostic approaches, government health insurance policies, and rising disposable income. Diabetes is affecting a huge number of geriatric populations in India post-COVID-19, which is propelling the diabetic retinopathy treatment market in the region. 

Leading Players in the Diabetic Retinopathy Treatment Market

Other key players in the market include Kubota Pharmaceutical Holdings Co., Novartis AG, Regeneron Pharmaceuticals, Inc., Pfizer Inc., Bayer AG, Allergan Plc., and ThromboGenics NV.

Key Questions Answered in the Diabetic Retinopathy Treatment Market

• What was the diabetic retinopathy treatment market value in 2025? 
• What is the diabetic retinopathy treatment market forecast outlook for 2026-2035?  
• What is market segmentation based on indication? 
• How does segmentation by treatment type influence market dynamics?   
• Who are the end-users in the market? 
• What are the major factors aiding the diabetic retinopathy treatment market demand?  
• How has the market performed so far and how is it anticipated to perform in the coming years? 
• What are the market's major drivers, opportunities, and restraints?  
• Which country is expected to experience expedited growth during the forecast period?  
• What are the major diabetic retinopathy treatment market trends?
• Which indication is expected to dominate the market? 
• Which treatment type will lead the market segment? 
• Which end-user will lead the market?
• Who are the key players involved in the diabetic retinopathy treatment market? 
• What is the patent landscape of the market? 
• What are the current unmet needs and challenges in the market?
• How are partnerships, collaborations, mergers, and acquisitions among the key market players shaping the market dynamics?

Diabetic Retinopathy Treatment Market Report Snapshots

Diabetic Retinopathy Treatment Companies